Sagimet Biosciences Inc. (NASDAQ: SGMT) Stock Information | RedChip

Sagimet Biosciences Inc. (NASDAQ: SGMT) Listen to this Section


$2.75
-0.0100 ( -0.36% ) 250.1K

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Market Data


Open


$2.75

Previous close


$2.76

Volume


250.1K

Market cap


$87.76M

Day range


$2.70 - $2.87

52 week range


$2.13 - $20.71

Insider Ownership Transactions

Total Amount Purchased: -406,224.00 | $ -1,117,116.00

Date Type Amount Purchased Purchaser
2024-08-05 Sale -113895.00 Jarrett Jennifer
2024-08-05 Sale -113895.00 Phillips Anne M.
2024-07-25 Sale -23625.00 Kemble George
2024-07-23 Sale -8357.00 Martins Eduardo Bruno
2024-07-23 Sale -10914.00 Rozek Elizabeth
2024-07-23 Sale -14062.00 Kemble George
2024-06-07 Sale -51459.00 SEIDENBERG BETH C
2024-06-07 Sale -51459.00 Parsey Merdad
2024-06-07 Sale -9279.00 Walbert Timothy P
2024-06-07 Sale -9279.00 Hoelscher Paul W.

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 60 Aug 14, 2024
8-k 8K-related 50 Aug 14, 2024
3 Insider transactions 2 Aug 05, 2024
3 Insider transactions 2 Aug 05, 2024
4 Insider transactions 1 Aug 05, 2024
4 Insider transactions 1 Aug 05, 2024
8-k 8K-related 13 Aug 01, 2024
4 Insider transactions 1 Jul 25, 2024
4 Insider transactions 1 Jul 23, 2024
4 Insider transactions 1 Jul 23, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.